Source:http://linkedlifedata.com/resource/pubmed/id/20594415
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-7-2
|
pubmed:abstractText |
Several rodent studies have demonstrated that fibrate drugs can activate peroxisome proliferator-activated receptor alpha (PPARalpha) and increase reactive oxygen species (ROS) production. The persistence of strong PPARalpha activation is considered to be a possible mechanism related to the adverse effects of these agents in humans. We recently found that bezafibrate-treated mice at clinically-relevant doses (10 mg/kg/day) exhibited similar pharmacokinetics to humans, but were different from previous rodent data (> 50 mg/kg/day). To examine whether clinical doses of bezafibrate do in fact activate PPARalpha and increase hepatic oxidative stress in mice, we administered bezafibrate to wild-type and Ppara-null mice at high (100 mg/kg/day) or low (10 mg/kg/day) doses and assessed ROS-related pathways in the liver. High-dose bezafibrate increased hepatic lipid peroxides in a PPARalpha-dependent manner, likely from discordant induction of PPARalpha-regulated ROS-generating enzymes (acyl-CoA oxidase, cytochrome P450 4A, and NADPH oxidase) and enhancement of mitochondrial beta-oxidation. The treatment also activated protein kinase C and phosphatidylinositol-3-kinase in wild-type mice only, suggesting an association between strong PPARalpha activation and an altered cell signaling cascade. Meanwhile, low-dose bezafibrate reduced serum/liver triglycerides in both genotypes without activating PPARalpha or enhancing hepatic oxidative stress. These results may support the safety of bezafibrate treatment at clinically-relevant doses.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antioxidants,
http://linkedlifedata.com/resource/pubmed/chemical/Bezafibrate,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C,
http://linkedlifedata.com/resource/pubmed/chemical/Reactive Oxygen Species
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1743-2928
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
123-30
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:20594415-Animals,
pubmed-meshheading:20594415-Antioxidants,
pubmed-meshheading:20594415-Bezafibrate,
pubmed-meshheading:20594415-Humans,
pubmed-meshheading:20594415-Hypolipidemic Agents,
pubmed-meshheading:20594415-Liver,
pubmed-meshheading:20594415-Mice,
pubmed-meshheading:20594415-Mice, Knockout,
pubmed-meshheading:20594415-Oxidative Stress,
pubmed-meshheading:20594415-PPAR alpha,
pubmed-meshheading:20594415-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:20594415-Protein Kinase C,
pubmed-meshheading:20594415-Random Allocation,
pubmed-meshheading:20594415-Reactive Oxygen Species
|
pubmed:year |
2010
|
pubmed:articleTitle |
Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice.
|
pubmed:affiliation |
Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
|
pubmed:publicationType |
Journal Article
|